Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19618698 | 0.84 | RECQL (0.35) | NPSR1ALDH1A1KDM4EHPGDLMNA | |
| SCHEMBL941690 | 0.80 | KDM4E (0.41) | MAPTL3MBTL1ALDH1A1KDM4EHPGD | |
| SCHEMBL908755 | 0.80 | KMT2A (0.35) | NPSR1MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL4062800 | 0.72 | ALDH1A1 (0.40) | NPSR1MAPTL3MBTL1CYP1A2CYP2C9 | |
| SCHEMBL10361017 | 0.72 | ALDH1A1 (0.46) | MAPTL3MBTL1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL23138142 | 0.72 | CYP1A2 (0.39) | NPSR1CYP1A2CYP2C9ALDH1A1LMNA | |
| SCHEMBL29115650 | 0.72 | CYP1A2 (0.39) | NPSR1CYP1A2CYP2C9ALDH1A1LMNA | |
| SCHEMBL15880689 | 0.72 | TSHR (0.42) | NPSR1MAPTL3MBTL1CYP1A2ALDH1A1 | |
| SCHEMBL2936341 | 0.72 | ADORA2A (0.34) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL2962859 | 0.71 | CYP1A2 (0.39) | NPSR1MAPTL3MBTL1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708371-B2 | Process for making beta 3 agonists and intermediates | MERCK SHARP & DOHME CORP. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20210221815-A1 | Process for Making Beta 3 Agonists and Intermediates | MERCK SHARP & DOHME CORP. (US) | 2021-07-22 | — | — | US | disclosed |
| US-20200031838-A1 | Process for Making Beta 3 Agonists and Intermediates | MERCK SHARP & DOHME CORP. (US) | 2020-01-30 | — | — | US | disclosed |
| US-10435410-B2 | Process for making beta 3 agonists and intermediates | MERCK SHARP & DOHME CORPORATION (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190016729-A1 | PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES | MERCK SHARP & DOHME CORP. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180065973-A1 | PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES | MERCK SHARP & DOHME CORP. (US) | 2018-03-08 | — | — | US | disclosed |
| US-9822121-B2 | Process for making beta 3 agonists and intermediates | MERCK SHARP & DOHME CORP. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160176884-A1 | Process for Making Beta 3 Agonists and Intermediates | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | US | disclosed |
| US-20150087832-A1 | PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES | MERCK SHARP & DOHME, CORP. (US) | 2015-03-26 | — | — | US | disclosed |
| WO-2013062881-A1 | PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176884-A1 | Process for Making Beta 3 Agonists and Intermediates | ADRB3, ADRB2, ADRB1 | NPSR1 269/4885MAPT 2876/4885L3MBTL1 4500/4885 |
| US-20150087832-A1 | PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES | ADRB3, ADRB2, ADRB1 | NPSR1 269/4885MAPT 2876/4885L3MBTL1 4500/4885 |
| US-20210221815-A1 | Process for Making Beta 3 Agonists and Intermediates | ADRB3, ADRB2, ADRB1 | NPSR1 269/4885MAPT 2876/4885L3MBTL1 4500/4885 |
| US-10435410-B2 | Process for making beta 3 agonists and intermediates | ADRB3, ADRB2, ADRB1 | NPSR1 269/4885MAPT 2876/4885L3MBTL1 4500/4885 |
| US-20180065973-A1 | PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES | ADRB3, ADRB2, ADRB1 | NPSR1 269/4885MAPT 2876/4885L3MBTL1 4500/4885 |
| US-20190016729-A1 | PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES | ADRB3, ADRB2, ADRB1 | NPSR1 269/4885MAPT 2876/4885L3MBTL1 4500/4885 |
| US-11708371-B2 | Process for making beta 3 agonists and intermediates | ADRB3, ADRB2, ADRB1 | NPSR1 269/4885MAPT 2876/4885L3MBTL1 4500/4885 |
| US-20200031838-A1 | Process for Making Beta 3 Agonists and Intermediates | ADRB3, ADRB2, ADRB1 | NPSR1 269/4885MAPT 2876/4885L3MBTL1 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.